| Year |
Citation |
Score |
| 2024 |
Panayi N, Schulz P, He P, Hanna B, Lifshitz J, Rowe RK, Sierks MR. Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits. Molecular Neurobiology. PMID 38411868 DOI: 10.1007/s12035-024-04035-5 |
0.349 |
|
| 2023 |
Panayi N, Schulz P, He P, Hanna B, Lifshitz J, Rowe R, Sierks MR. Traumatic brain injury in mice generates early-stage Alzheimer's disease related protein pathology that correlates with neurobehavioral deficits. Research Square. PMID 37205508 DOI: 10.21203/rs.3.rs-2865501/v1 |
0.347 |
|
| 2021 |
Trudler D, Nazor KL, Eisele YS, Grabauskas T, Dolatabadi N, Parker J, Sultan A, Zhong Z, Goodwin MS, Levites Y, Golde TE, Kelly JW, Sierks MR, Schork NJ, Karin M, et al. Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33833060 DOI: 10.1073/pnas.2025847118 |
0.309 |
|
| 2021 |
He P, Schulz P, Sierks MR. A conformation specific antibody against Oligomeric β-Amyloid Restores Neuronal Integrity in a Mouse Model of Alzheimer's Disease. The Journal of Biological Chemistry. 100241. PMID 33428939 DOI: 10.1074/jbc.RA120.015327 |
0.431 |
|
| 2020 |
He P, Schulz P, Sierks MR. A conformation specific antibody against Oligomeric β-Amyloid Restores Neuronal Integrity in a Mouse Model of Alzheimer's Disease. The Journal of Biological Chemistry. PMID 33376140 DOI: 10.1074/jbc.RA120.015327 |
0.431 |
|
| 2020 |
Venkataraman L, He P, Khan G, Harris BT, Sierks MR. Isolation and characterization of antibody fragments selective for human FTD brain derived TDP-43 variants. Bmc Neuroscience. 21: 36. PMID 32887544 DOI: 10.1186/S12868-020-00586-0 |
0.324 |
|
| 2020 |
Venkataraman L, He P, Schulz P, Sierks MR. Isolation and characterization of antibody fragment selective for human Alzheimer's disease brain-derived tau variants. Neurobiology of Aging. 94: 7-14. PMID 32497877 DOI: 10.1016/j.neurobiolaging.2020.04.014 |
0.381 |
|
| 2019 |
He P, Xin W, Schulz P, Sierks MR. Bispecific Antibody Fragment Targeting APP and Inducing α-Site Cleavage Restores Neuronal Health in an Alzheimer's Mouse Model. Molecular Neurobiology. PMID 31041656 DOI: 10.1007/s12035-019-1597-z |
0.448 |
|
| 2017 |
Roher AE, Kokjohn TA, Clarke SG, Sierks MR, Maarouf CL, Serrano GE, Sabbagh MS, Beach TG. APP/Aβ structural diversity and Alzheimer's disease pathogenesis. Neurochemistry International. PMID 28811267 DOI: 10.1016/J.Neuint.2017.08.007 |
0.45 |
|
| 2017 |
Williams SM, Schulz P, Rosenberry TL, Caselli RJ, Sierks MR. Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 28372328 DOI: 10.3233/JAD-161116 |
0.368 |
|
| 2016 |
Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, ... ... Sierks M, et al. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Scientific Reports. 6: 19393. PMID 26786552 DOI: 10.1038/Srep19393 |
0.549 |
|
| 2015 |
Williams SM, Schulz P, Sierks MR. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. The European Journal of Neuroscience. PMID 26332448 DOI: 10.1111/ejn.13056 |
0.379 |
|
| 2015 |
Williams SM, Venkataraman L, Tian H, Khan G, Harris BT, Sierks MR. Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis. Journal of Visualized Experiments : Jove. PMID 25742170 DOI: 10.3791/52584 |
0.533 |
|
| 2015 |
Tian H, Davidowitz E, Lopez P, He P, Schulz P, Moe J, Sierks MR. Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiology of Aging. 36: 1342-55. PMID 25616912 DOI: 10.1016/J.Neurobiolaging.2014.12.002 |
0.581 |
|
| 2014 |
Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S, Kosberg K, Shen J, Rockenstein E, Patrick C, Adame A, Gonzalez T, Sierks M, Masliah E. ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 1753-67. PMID 25008355 DOI: 10.1038/Mt.2014.129 |
0.408 |
|
| 2014 |
Yang G, Velgos SN, Boddapati SP, Sierks MR. Probing antibody-antigen interactions Microbiology Spectrum. 2: 1-13. DOI: 10.1128/microbiolspec. AID-0010-2013 |
0.711 |
|
| 2013 |
Tian H, Davidowitz E, Lopez P, Emadi S, Moe J, Sierks M. Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. International Journal of Cell Biology. 2013: 260787. PMID 24159335 DOI: 10.1155/2013/260787 |
0.612 |
|
| 2013 |
Kasturirangan S, Reasoner T, Schulz P, Boddapati S, Emadi S, Valla J, Sierks MR. Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnology Progress. 29: 463-71. PMID 23359572 DOI: 10.1002/Btpr.1698 |
0.758 |
|
| 2012 |
Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR. Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP. Journal of Alzheimer's Disease : Jad. 28: 961-9. PMID 22156046 DOI: 10.3233/Jad-2011-111196 |
0.75 |
|
| 2012 |
Kasturirangan S, Li L, Emadi S, Boddapati S, Schulz P, Sierks MR. Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form. Neurobiology of Aging. 33: 1320-8. PMID 21067847 DOI: 10.1016/J.Neurobiolaging.2010.09.020 |
0.777 |
|
| 2012 |
Vattipalli K, Brandigampala S, McGraw C, Chatterjee G, Kasturirangan S, Schulz P, Sierks M, Prasad S. Nanotextured material for applications in CSF sample screening and characterization Materials Research Society Symposium Proceedings. 1466: 26-31. DOI: 10.1557/Opl.2012.1200 |
0.43 |
|
| 2011 |
Sierks MR, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integrative Biology : Quantitative Biosciences From Nano to Macro. 3: 1188-96. PMID 22076255 DOI: 10.1039/c1ib00018g |
0.434 |
|
| 2011 |
Boddapati S, Levites Y, Sierks MR. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. Journal of Molecular Biology. 405: 436-47. PMID 21073877 DOI: 10.1016/J.Jmb.2010.10.054 |
0.786 |
|
| 2010 |
Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. Bmc Neuroscience. 11: 57. PMID 20433710 DOI: 10.1186/1471-2202-11-57 |
0.707 |
|
| 2010 |
Kasturirangan S, Boddapati S, Sierks MR. Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. Biochemistry. 49: 4501-8. PMID 20429609 DOI: 10.1021/Bi902030M |
0.78 |
|
| 2010 |
Wang MS, Boddapati S, Sierks MR. Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid. Biotechnology Progress. 26: 1172-9. PMID 20306540 DOI: 10.1002/Btpr.396 |
0.78 |
|
| 2010 |
Kasturirangan S, Sierks M. Targeted hydrolysis of beta-amyloid with engineered antibody fragments Current Alzheimer Research. 7: 214-222. PMID 20088808 DOI: 10.2174/156720510791050876 |
0.572 |
|
| 2009 |
Wang M, Boddapati S, Sierks M. Response letter to comments on "Cyclodextrins promote protein aggregation posing risks for therapeutic applications". Biochemical and Biophysical Research Communications. 390: 1426-7. PMID 19852940 DOI: 10.1016/J.Bbrc.2009.10.073 |
0.724 |
|
| 2009 |
Kasturirangan S, Brune D, Sierks M. Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. Biotechnology Progress. 25: 1054-63. PMID 19572401 DOI: 10.1002/Btpr.190 |
0.416 |
|
| 2009 |
Wang MS, Boddapati S, Sierks MR. Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochemical and Biophysical Research Communications. 386: 526-31. PMID 19540204 DOI: 10.1016/J.Bbrc.2009.06.077 |
0.779 |
|
| 2009 |
Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. Plos One. 4: e5727. PMID 19492089 DOI: 10.1371/Journal.Pone.0005727 |
0.399 |
|
| 2009 |
Yuan B, Sierks MR. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neuroscience Letters. 459: 16-8. PMID 19394405 DOI: 10.1016/j.neulet.2009.04.046 |
0.31 |
|
| 2009 |
Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 918-29. PMID 19176801 DOI: 10.1523/Jneurosci.3952-08.2009 |
0.39 |
|
| 2009 |
Wang MS, Zameer A, Emadi S, Sierks MR. Characterizing antibody specificity to different protein morphologies by AFM. Langmuir : the Acs Journal of Surfaces and Colloids. 25: 912-8. PMID 19090748 DOI: 10.1021/la8025914 |
0.362 |
|
| 2008 |
Zameer A, Kasturirangan S, Emadi S, Nimmagadda SV, Sierks MR. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. Journal of Molecular Biology. 384: 917-28. PMID 18929576 DOI: 10.1016/j.jmb.2008.09.068 |
0.495 |
|
| 2008 |
Nannenga BL, Zameer A, Sierks MR. Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates. Febs Letters. 582: 517-22. PMID 18230361 DOI: 10.1016/J.Febslet.2008.01.014 |
0.353 |
|
| 2008 |
Marcus WD, Wang H, Lindsay SM, Sierks MR. Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy. Nanomedicine : Nanotechnology, Biology, and Medicine. 4: 1-7. PMID 18201941 DOI: 10.1016/j.nano.2007.11.003 |
0.419 |
|
| 2008 |
Boddapati SP, Sierks MR. P2-417: Beta-site specific ScFv's to decrease Abeta generation and toxicity in Alzheimer's disease Alzheimer's & Dementia. 4: T495-T496. DOI: 10.1016/J.Jalz.2008.05.1496 |
0.748 |
|
| 2007 |
Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. Journal of Molecular Biology. 368: 1132-44. PMID 17391701 DOI: 10.1016/j.jmb.2007.02.089 |
0.332 |
|
| 2006 |
Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 2576-8. PMID 17068112 DOI: 10.1096/Fj.06-6463Fje |
0.398 |
|
| 2006 |
Barkhordarian H, Emadi S, Schulz P, Sierks MR. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Engineering, Design & Selection : Peds. 19: 497-502. PMID 16984950 DOI: 10.1093/protein/gzl036 |
0.32 |
|
| 2006 |
Zameer A, Schulz P, Wang MS, Sierks MR. Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry. 45: 11532-9. PMID 16981713 DOI: 10.1021/bi060601o |
0.497 |
|
| 2006 |
Marcus WD, Wang H, Lohr D, Sierks MR, Lindsay SM. Isolation of an scFv targeting BRG1 using phage display with characterization by AFM. Biochemical and Biophysical Research Communications. 342: 1123-9. PMID 16513088 DOI: 10.1016/J.Bbrc.2006.02.073 |
0.345 |
|
| 2005 |
Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiology of Disease. 20: 74-81. PMID 16137568 DOI: 10.1016/j.nbd.2005.02.003 |
0.475 |
|
| 2005 |
Kanapathipillai M, Lentzen G, Sierks M, Park CB. Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid. Febs Letters. 579: 4775-80. PMID 16098972 DOI: 10.1016/J.Febslet.2005.07.057 |
0.559 |
|
| 2004 |
Liu R, McAllister C, Lyubchenko Y, Sierks MR. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry. 43: 9999-10007. PMID 15287727 DOI: 10.1021/Bi0492354 |
0.476 |
|
| 2004 |
Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, Lyubchenko Y, Goud G, Sierks MR. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry. 43: 6959-67. PMID 15170333 DOI: 10.1021/Bi049933O |
0.497 |
|
| 2004 |
Liu R, McAllister C, Lyubchenko Y, Sierks MR. Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. Journal of Neuroscience Research. 75: 162-71. PMID 14705137 DOI: 10.1002/Jnr.10859 |
0.442 |
|
| 2004 |
Zameer A, Liu R, Sierks M. P4-420 Single chain FV antibodies against 25–35 peptide fragment of amyloid-β: potential therapeutic for Alzheimers disease Neurobiology of Aging. 25: S593. DOI: 10.1016/S0197-4580(04)81976-6 |
0.47 |
|
| 2004 |
Liu R, Sierks M. P4-354 Anti beta-amyloid (Aβ) SCFV inhibits Aβ aggregation and neurotoxicity Neurobiology of Aging. 25: S575-S576. DOI: 10.1016/S0197-4580(04)81912-2 |
0.518 |
|
| 2004 |
Taguchi H, Planque S, Nishiyama Y, Sierks MR, Szabo P, Weksler ME, Paul S. P4-331 Catalytic hydrolysis of amyloid β-peptide (Aβ) by human antibodies Neurobiology of Aging. 25: S569. DOI: 10.1016/S0197-4580(04)81889-X |
0.343 |
|
| 2003 |
Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry. 42: 14328-34. PMID 14640701 DOI: 10.1021/bi035038d |
0.417 |
|
| 2001 |
Goud GN, Artsaenko O, Bols M, Sierks M. Specific glycosidase activity isolated from a random phage display antibody library Biotechnology Progress. 17: 197-202. PMID 11170499 DOI: 10.1021/Bp0001258 |
0.321 |
|
| Show low-probability matches. |
